Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIPEC Combined With Sintilimab in Gastric Cancer With Peritoneal Metastasis
NCT05648487Phase 2Not yet recruiting
- Sponsor
- Cancer Center of Guangzhou Medical University
- Start
- Jan 2023
- Primary completion
- Mar 2025
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of sintilimab in gastric cancer (GC), sponsored by Cancer Center of Guangzhou Medical University. Planned start Jan 2023; status: not yet recruiting.
02
Drugs
sintilimab
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT05648487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05648487.